Dermisonics, Inc.

IRVINE, Calif., March 22 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB - News), a pioneer in the development of painless injection-free ultrasonic transdermal drug-delivery technologies with broad pharmaceutical and consumer applications, announced today that the Company has agreed to sell a total of 7.2 million common shares of the Company's capital stock to two Luxembourg-based SICAV funds for net proceeds of $4,134,240. The placement will be completed in reliance upon the exemption from the registration requirements of the Securities Act afforded by Regulation S as promulgated under the Securities Act of 1933.

Comment - These seem like good financing terms for a company on the OTCBB. Congratulations to Management. Great job !!!!!